Related Experiment Videos

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside

Catharine C Bulik¹, Justin C Bader², Li Zhang³

¹Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY, 12305, USA. cbulik@icpd.com.

Journal of Pharmacokinetics and Pharmacodynamics

|February 16, 2018

Abstract:

The original version of this article contained incorrect Supplementary Files. The correct Supplementary Files are published with this erratum.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development.

Antimicrobial agents and chemotherapy·2026

A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers.

Clinical pharmacology in drug development·2026

Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.

Antimicrobial agents and chemotherapy·2025

Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia.

Antimicrobial agents and chemotherapy·2025

Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.

Antimicrobial agents and chemotherapy·2024

The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.

The Journal of antimicrobial chemotherapy·2024

See all related articles